Outpatient intensive induction chemotherapy for acute myeloid leukemia and high-risk myelodysplastic syndrome

To improve patient quality of life and reduce health care costs, many conditions formerly thought to require inpatient care are now treated in the outpatient setting. Outpatient induction chemotherapy for acute myeloid leukemia (AML) may confer similar benefits. This possibility prompted a pilot stu...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Blood Adv
Egile Nagusiak: Mabrey, Frances Linzee, Gardner, Kelda M., Shannon Dorcy, Kathleen, Perdue, Andrea, Smith, Heather A., Davis, Alicyn M., Hammer, Cody, Rizzuto, Donelle, Jones, Sunny, Quach, Kim, Scott, Bart L., Hendrie, Paul C., Percival, Mary-Elizabeth M., Walter, Roland B., Appelbaum, Frederick R., Estey, Elihu H., Becker, Pamela S.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: American Society of Hematology 2020
Gaiak:
Clinical Trials and Observations
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7042997/
https://ncbi.nlm.nih.gov/pubmed/32074276
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2019000707
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak